文献速递认知障碍与痴呆

痴呆患者脑脊液阿尔茨海默病生物标志物研究

Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia.
PubMed 文献 · JAMA Neurol · 2025-01-01

基于瑞典 SveDem 登记库的横断面研究(12 年),纳入 13 882 例痴呆患者,分析脑脊液 Aβ1-42、t-tau、p-tau181 与诊断及 MMSE 的关联。多数临床诊断 AD 者具 AD 样生物标志物谱,其他痴呆亦可见但较少;标志物与认知的关联主要在 AD 相关诊断中。

要点

  • 临床诊断 AD 者多数有脑脊液 AD 样生物标志物证据。
  • 其他痴呆亦可见 AD 样生物标志物谱,但比例较低。
  • 脑脊液标志物与 MMSE 的关联主要见于 AD 相关诊断。

核心结论

  • Aβ 相关病理是 AD 的定义性特征,多数临床诊断 AD 者有生物标志物证据,其他痴呆亦可见但较少。
  • 脑脊液 AD 样病理标志物浓度与认知功能相关,但主要见于 AD 相关诊断(早发和晚发 AD)患者。

研究设计与样本

  • 横断面研究,为期 12 年(2010 年 10 月 5 日至 2022 年 8 月 31 日)。
  • 瑞典认知障碍和痴呆登记库(SveDem)临床数据与 AD 核心脑脊液生物标志物(Aβ1-42、t-tau、p-tau181)常规检测结果合并。
  • 纳入痴呆诊断后 3 年内登记有完整脑脊液 Aβ1-42、t-tau、p-tau 检测的个体。
  • 共纳入 13 882 例(女性 7328 例[53%],男性 6554 例[47%];中位[IQR]年龄 74[68-79]岁)。

主要发现

  • 除 AD 组(早发 AD 1150 例[68%];晚发 AD 3392 例[65%];混合 AD 和血管性痴呆 1038 例[52%])外,痴呆未特指组有明确 AD 样生物标志物谱者最多(443 例[25%])。
  • 帕金森病痴呆组和额颞叶痴呆组有明确 AD 样生物标志物谱者比例最小(分别为 15 例[9%]和 51 例[8%])。
  • MMSE 评分与脑脊液 Aβ1-42 的关联见于晚发 AD、血管性痴呆、额颞叶痴呆和痴呆未特指组。
  • MMSE 评分与 t-tau 的关联见于晚发 AD、早发 AD 和痴呆未特指组;与 p-tau181 的关联见于早发 AD。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The defining pathological features of Alzheimer disease (AD) may also be contributing factors in other dementias. OBJECTIVE: To examine the prevalence of β-amyloid (Aβ) and tau pathophysiological changes as indicated by cerebrospinal fluid biomarkers, as well as their association with clinical disease progression, across a broad range of dementias. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional study with a duration of 12 years (October 5, 2010, to August 31, 2022), clinical data from the Swedish registry for cognitive disorders and dementia (SveDem) were merged with clinical routine biomarker measurements of the core cerebrospinal fluid biomarkers of AD: Aβ1-42, total tau (t-tau), and phosphorylated tau 181 (p-tau181). Participants were individuals with a dementia diagnosis who had a complete set of cerebrospinal fluid Aβ1-42, t-tau, and p-tau measurements registered less than 3 years after the date of diagnosis. Data were analyzed from April to November 2023. EXPOSURES: Age, sex, and dementia diagnosis. MAIN OUTCOMES AND MEASURES: Biomarker profiles in relation to diagnosis and cognitive status as indicated by Mini-Mental State Examination (MMSE) scores. RESULTS: Among 15 004 individuals with a dementia diagnosis in the SveDem database, 13 882 were included in this study (7328 females [53%], 6554 males [47%]; median [IQR] age, 74 [68-79] years). Apart from the AD groups (early-onset AD, 1150 [68%]; late-onset AD, 3392 [65%]; mixed AD and vascular dementia, 1038 [52%]), the dementia not otherwise specified group had the most patients (443 [25%]) with a clear AD-like biomarker profile, while Parkinson disease dementia and the frontotemporal dementia groups had the smallest shares (15 [9%] and 51 [8%], respectively). MMSE score was associated with cerebrospinal fluid Aβ1-42 in late-onset AD, vascular dementia, frontotemporal dementia, and dementia not otherwise specified; with t-tau in late-onset AD, early-onset AD, and dementia not otherwise specified; and with p-tau181 in early-onset AD. CONCLUSIONS AND RELEVANCE: Aβ-related pathology is a defining feature of AD, and most patients clinically diagnosed with AD have biomarker evidence of this process, but the same is found in other dementias, although less commonly. Cerebrospinal fluid biomarker concentrations of AD-like pathology were associated with cognitive function but mainly in patients with an AD-related diagnosis (early- and late-onset AD).

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Skillbäck TB, Jönsson L, Skoog I, et al. Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia. JAMA Neurol. 2025. PMID: 40293734. doi:10.1001/jamaneurol.2025.0693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。